MyFinsight
Home
Blog
About
Contact
Download
Download image
Comprehensive (loss) income
-$45,422K
(-196.82%↓ Y/Y)
Provision for pension
benefit obligation
-$55K
(-214.58%↓ Y/Y)
Net (loss) income
-$44,503K
(-194.92%↓ Y/Y)
Unrealized loss on
available-for-sale securities
$974K
(4538.10%↑ Y/Y)
Interest income
$5,591K
(62.58%↑ Y/Y)
Net (loss) income
before income taxes
-$44,451K
(-193.18%↓ Y/Y)
Income tax benefit
(provision)
$52K
(-93.67%↓ Y/Y)
Total other income
$5,583K
(52.08%↑ Y/Y)
Foreign currency
exchange (gain) loss
-$8K
(-104.62%↓ Y/Y)
(loss) income from
operations
-$50,034K
(-213.62%↓ Y/Y)
Collaboration revenue
$4,210K
(-95.04%↓ Y/Y)
Total operating
expenses
$54,244K
(32.65%↑ Y/Y)
Research and development
$44,069K
(36.90%↑ Y/Y)
General and
administrative
$10,175K
(16.91%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
Monte Rosa Therapeutics, Inc. (GLUE)
Monte Rosa Therapeutics, Inc. (GLUE)